{"id":"W4213356935","doi":"10.1200/jco.2022.40.6_suppl.338","title":"Efficacy and safety of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in the East Asian subset of patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Clinical endpoint; Odds ratio; Population; Clinical trial; Confidence interval; Oncology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044493,0.0009085901,0.001900801,0.0004062225,0.0003655032,0.000815711,0.0006419298,0.0008000836,0.002383721],"category_scores_gemma":[0.001821865,0.0004581995,0.002069671,0.0004564777,0.0007312779,0.000771645,0.0004210907,0.002294579,0.0003815305],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007949155,"about_ca_system_score_gemma":0.001311211,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005675902,"about_ca_topic_score_gemma":0.001912991,"domain_scores_codex":[0.9988451,0.0007599721,0.00009304169,0.0001312574,0.00009016112,0.00008048057],"domain_scores_gemma":[0.9987754,0.000345715,0.0004284528,0.00008254969,0.00006758767,0.0003001564],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9411502,0.005637989,0.006754469,0.001042911,0.003472335,0.00007645383,0.000133236,0.0009035199,0.003805198,0.0001245571,0.001286883,0.03561242],"study_design_scores_gemma":[0.7325218,0.226531,0.02923638,0.0001133399,0.005088934,0.0003392477,0.00009841995,0.001117379,0.001888454,0.0003238978,0.002703867,0.00003717121],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.987776,0.006880419,0.0003579212,0.0004591414,0.0001025081,0.001516806,0.001063258,0.00003483169,0.001809063],"genre_scores_gemma":[0.9939334,0.001937232,0.0007105736,0.0005153702,0.0001057217,0.001240914,0.0008929937,0.00001207884,0.0006517126],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0044493,"threshold_uncertainty_score":0.02353036,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0947188487294451,"score_gpt":0.3856240920916396,"score_spread":0.2909052433621945,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}